Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB HY2019 P&L Consensus 

In € million HY 2019e
Average
HY 2019e
Median
Revenue  2,302 2,308 
Recurring EBIT 573  561 
Recurring EBITDA 696  702 
Net Profit* 420   411
Core EPS  2.49 2.51 

*attributable to UCB shareholders 

UCB HY2019 Product Sales Consensus 

In € million HY 2019e
Average
HY 2019e
Median
Cimzia 736  737 
Vimpat 606  608 
Keppra 385  384 
Briviact  98 99 
Neupro  156  153

 

UCB FY Consensus Product Sales Estimates (Average)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,515 1,537 1,550 1,543 1,506 1,439
Vimpat 1,099 1,230 1,329 1,422 1,248 850 693
Keppra  790 758 723 662 615 575 546
Briviact 142 217 286 355 414 471 513
Neupro 321 326 325 288 231 196 154
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab) 38   105  192  279 365   460
Midazolam nasal spray 9 23  42  60  79  92 
Bimekizumab 66  189  355   526
Rozanolixizumab (Rozimab/Roza)  42 125  218 
Padsevonil 12  37  90   146
Anti-Tau  0  0  0  50  125

  *in the next 5 years

UCB FY Consensus Earnings Estimates (Average)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,505 4,715  4,888 
Revenue  4,632 4,699 4,899 5,069
Recurring EBIT 1,105  1,046 1,154 1,280
Recurring EBITDA 1,398  1,327 1,436 1,560
Net Profit*  800 757 843 955
Core EPS (€) 4.78  4.62 5.08 5.68

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,516 1,553 1,559 1,554 1,537 1,401
Vimpat 1,099 1,238 1,334 1,413 1,236 843 710
Keppra 790 752 721 653 605 568 539
Briviact 142 214 297 372 429 474 531
Neupro 321 326 322 285 216 176 140
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab)  37 95   173  252  313 373 
Midazolam nasal spray 10  20  40  65   80 96 
Bimekizumab  0 50  150  350  520 
Rozanolixizumab (Rozimab/Roza)  0 12  105   219
Padsevonil 20   80  153
Anti-Tau  0  0 50  125 

 *in the next 5 years

UCB FY Consensus Earnings Estimates (Median)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,516 4,740  4,945 
Revenue  4,632 4,699 4,910 5,125
Recurring EBIT 1,105  1,045 1,157 1,280
Recurring EBITDA  1,398 1,334 1,445 1,563
Net Profit*  800  754 847 956
Core EPS (€)  4.78 4.65 5.10 5.69

*attributable to UCB shareholders

Downloads:
UCB FY & HY 2019 Consensus (Excel)
UCB HY 2019 Consensus (PDF)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 16 July, 2019



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.